Lantheus Holdings, Inc. (NASDAQ:LNTH) Shares Bought by Captrust Financial Advisors

Captrust Financial Advisors increased its stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 33.2% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 36,091 shares of the medical equipment provider's stock after acquiring an additional 9,005 shares during the quarter. Captrust Financial Advisors owned approximately 0.05% of Lantheus worth $3,961,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. CreativeOne Wealth LLC boosted its position in shares of Lantheus by 10.7% during the third quarter. CreativeOne Wealth LLC now owns 5,167 shares of the medical equipment provider's stock valued at $567,000 after buying an additional 499 shares during the last quarter. Glenmede Trust Co. NA purchased a new position in Lantheus in the 3rd quarter worth approximately $540,000. Prosperity Financial Group Inc. lifted its stake in Lantheus by 12.6% in the 3rd quarter. Prosperity Financial Group Inc. now owns 4,137 shares of the medical equipment provider's stock worth $454,000 after purchasing an additional 464 shares in the last quarter. Pekin Hardy Strauss Inc. purchased a new position in Lantheus during the 3rd quarter valued at approximately $225,000. Finally, Centaurus Financial Inc. increased its position in Lantheus by 13.0% in the third quarter. Centaurus Financial Inc. now owns 3,103 shares of the medical equipment provider's stock worth $341,000 after purchasing an additional 357 shares during the last quarter. 99.06% of the stock is currently owned by institutional investors.

Lantheus Stock Up 0.4 %

NASDAQ LNTH traded up $0.33 on Wednesday, reaching $88.84. The stock had a trading volume of 448,019 shares, compared to its average volume of 1,020,414. The firm has a market capitalization of $6.18 billion, a price-to-earnings ratio of 14.73 and a beta of 0.45. Lantheus Holdings, Inc. has a 12-month low of $50.20 and a 12-month high of $126.89. The stock has a fifty day moving average price of $100.44 and a two-hundred day moving average price of $97.49.

Analyst Ratings Changes

A number of analysts have recently issued reports on LNTH shares. Redburn Atlantic assumed coverage on shares of Lantheus in a research note on Tuesday, September 3rd. They set a "buy" rating and a $175.00 target price for the company. JMP Securities decreased their price target on Lantheus from $125.00 to $112.00 and set a "market outperform" rating for the company in a research note on Thursday, November 7th. Truist Financial reiterated a "buy" rating and set a $120.00 price target (down previously from $135.00) on shares of Lantheus in a research note on Friday, November 8th. Finally, StockNews.com cut Lantheus from a "buy" rating to a "hold" rating in a report on Thursday, November 21st. Two investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $125.71.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.